STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )
Immunology · 2026
DOI: 10.1111/imm.70121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, 2026. Verfasst von Roshni Bibi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology and Gene Technology Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankula…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Epigenesis, Genetic, STAT2 Transcription Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Indian Council of Medical Research, Ministry of Tribal Affairs, Govt. of India.
Abstract (Originalsprache)
Non‐small cell lung cancer (NSCLC) is an aggressive malignancy necessitating innovative therapeutic approaches to augment antitumour immunity. Our study examined the function of the STAT2 protein in CD4 + T helper cells, which are essential for the immune response to cancer. We utilised CRISPR/Cas9 to ablate STAT2 in CD4 + T cells from stage I NSCLC patients ( n = 30), assessing its impact on cellular function and diverse epigenetic pathways. Our findings indicate that the depletion of STAT2 markedly enhances the anti‐cancer efficacy of T lymphocytes. Deletion of STAT2 diminished oxidative stress, enhanced the synthesis of advantageous TH1 cytokines. STAT2 depletion reduced DNA methylation and R‐loop formation. T cells deficient in STAT2 showed enhanced efficacy in activating cytotoxic T lymphocytes to eliminate cancer cells. These findings identify STAT2 as a crucial regulator of immune function in the lung cancer microenvironment. Targeted STAT2 inhibition in tumour‐reactive T cells may reinstate anti‐tumour immunity, although systemic inhibition requires further research on targeted intervention strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Immunology and Gene Technology Lab, Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
- Department Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India.
ORCID-Profile: Roshni Bibi, Koustav Sarkar
Förderung
- Indian Council of Medical Research
- Ministry of Tribal Affairs, Govt. of India
Zitieren
APA
Bibi, R., George, M., & Sarkar, K. (2026). STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ). Immunology. https://doi.org/10.1111/imm.70121
Vancouver
Bibi R, George M, Sarkar K. STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC ). Immunology. 2026. doi:10.1111/imm.70121
BibTeX
@article{Bibi2026,
author = {Bibi, Roshni and George, Melvin and Sarkar, Koustav},
title = {STAT2 Mediated Epigenetic and Epitranscriptomic Regulation of CD4 + T Helper Cell Differentiation in Non‐Small Cell Lung Cancer ( NSCLC )},
journal = {Immunology},
year = {2026},
doi = {10.1111/imm.70121}
}
EUVIMED